Wojciech Michowski

Wojciech Michowski

Auto-generated profile, based on publicly available information

Wojciech Michowski

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LLLijun Liu
Lijun Liu
WMWojciech Michowski
Wojciech Michowski
AKAleksandra Kolodziejczyk
Aleksandra Kolodziejczyk
PSPiotr Sicinski
Piotr Sicinski

19 March 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SSSamanta Sharma
Samanta Sharma
TZTian Zhang
Tian Zhang
WMWojciech Michowski
Wojciech Michowski
VRVito W. Rebecca
Vito W. Rebecca
MXMin Xiao
Min Xiao
PSPiotr Sicinski
Piotr Sicinski
Significance: Melanomas are notorious due to their propensity to form lethal metastases. Currently, no treatments are available to stop the metastatic spread. We observed that in malignant melanomas, a protein called the cyclin-dependent kinase 5 (CDK5) is essential for melanoma metastasis. Using mouse and human melanoma cells, we demonstrated that in this tumor type CDK5 promotes the metastatic spread by directly phosphorylating a mesenchymal-type intermediate filament, vimentin. We found that a genetic shutdown of CDK5 in a mouse model of melanoma abrogated metastasis, while chemical inhibition of CDK5 kinase in mice carrying patient-derived tumors impeded the metastatic spread of tumor cells. Our results indicate that inhibition of CDK5 might represent a therapeutic strategy to block the metastatic dissemination of melanoma cells.